Yazici E, S Cilli A, Yazici AB, Baysan H, Ince M, Bosgelmez S, Bilgic S, Aslan B, Erol A. Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.
Clin Pract Epidemiol Ment Health 2017;
13:92-103. [PMID:
29081826 PMCID:
PMC5633702 DOI:
10.2174/1745017901713010092]
[Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 05/24/2017] [Accepted: 06/22/2017] [Indexed: 02/03/2023]
Abstract
Background:
This study investigates the antipsychotic use patterns of patients with schizophrenia and its correlations in their daily drug use patterns.
Methods:
Patients with schizophrenia who have regular records at two different community counselling centres (CCS) were included in the study. Information about their medications and sociodemographic data was recorded through face-to-face interviews and supporting information about their drug use patterns was obtained from their relatives/caregivers/nurse. The Clinical Global Impression Scale (severity of illness) and the General Assessment of Functionality scales were also administered.
Results:
Patients with schizophrenia used 2.0 ± 0.81 antipsychotics daily and 3.52 ± 2.55 pills (1–18). Seventy-one percent of the patients used two or more kinds of psychotropic drugs. The most frequently used antipsychotics were quetiapine, a second generation antipsychotic, and haloperidol, a typical antipsychotic. Clinical severity, regular visits to a CCS and use of depot antipsychotics were independent predictors for polypharmacy.
Conclusion:
The rate of polypharmacy use is high in Turkey. There are multiple risk factors related with polipharmacy. New studies should focus risk factors for preventing polypharmacy.
Collapse